Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer

Pfizer is expanding the reach of its BRAF-MEK combo as the pharma giant looks to further build up its oncology presence.

The FDA has approved Pfizer’s Braftovi and Mektovi for treating metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutations, the agency said Wednesday.